On Dec 06, major Wall Street analysts update their ratings for $Edwards Lifesciences (EW.US)$, with price targets ranging from $75 to $90.
Goldman Sachs analyst David Roman maintains with a buy rating, and adjusts the target price from $80 to $90.
Barclays analyst Matt Miksic maintains with a buy rating, and maintains the target price at $88.
UBS analyst Danielle Antalffy maintains with a hold rating, and adjusts the target price from $75 to $78.
TD Cowen analyst Josh Jennings maintains with a hold rating, and maintains the target price at $75.
Mizuho Securities analyst Anthony Petrone maintains with a buy rating, and sets the target price at $85.
Furthermore, according to the comprehensive report, the opinions of $Edwards Lifesciences (EW.US)$'s main analysts recently are as follows:
The outlook for Edwards Lifesciences appears increasingly positive following the company's analyst day and the introduction of new guidance. While the current valuation broadly mirrors expectations for Edwards' growth, continued adherence to this guidance could heighten investor interest, particularly leading up to moderate data revelations expected at TCT 2026.
Edwards Lifesciences presented its 2025 outlook and long-range plans during its Investor Day, addressing previous concerns about TAVR capacity issues and competitive pressures, which are anticipated to persist into 2025. Despite these challenges, the company's 2025 guidance excluding foreign exchange impacts was more optimistic than expected, projecting growth of 8%-10% compared to a consensus of 7.8%. This projection bolstered investor confidence, with analysts recognizing the company's solid positioning in attractive end-markets, multiple growth catalysts, and favorable valuation.
Following attendance at the annual Edwards Lifesciences analyst meeting, it was clear there is an emerging positive narrative for the company's future. The current market valuation of Edwards seems reasonable, pending further support from physician insights.
Edwards Lifesciences delivered a promising multiyear outlook during its annual investor day, reiterating its 2024 guidance and unveiling 2025 guidance that aligns with current market estimates.
Here are the latest investment ratings and price targets for $Edwards Lifesciences (EW.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间12月6日，多家华尔街大行更新了$爱德华生命科学 (EW.US)$的评级，目标价介于75美元至90美元。
高盛集团分析师David Roman维持买入评级，并将目标价从80美元上调至90美元。
巴克莱银行分析师Matt Miksic维持买入评级，维持目标价88美元。
瑞士银行分析师Danielle Antalffy维持持有评级，并将目标价从75美元上调至78美元。
TD Cowen分析师Josh Jennings维持持有评级，维持目标价75美元。
瑞穗证券分析师Anthony Petrone维持买入评级，目标价85美元。
此外，综合报道，$爱德华生命科学 (EW.US)$近期主要分析师观点如下：
爱德华生命科学的前景在公司分析师日和新指引的发布后似乎越来越积极。虽然目前的估值大致反映了对爱德华增长的预期，但持续遵循这一指引可能会提升投资者兴趣，特别是在预计将在TCt 2026上披露的温和数据之前。
爱德华生命科学在其投资者日上介绍了2025年的前景和长期计划，解决了关于TAVR产能问题和竞争压力的以往担忧，这些问题预计将持续到2025年。尽管面临这些挑战，公司在不考虑汇率期货影响的情况下发布的2025年指引比预期更加乐观，预计增长为8%-10%，而共识为7.8%。这一预测增强了投资者信心，分析师们认可公司在有吸引力的终端市场中的稳固定位、多重增长催化剂以及有利估值。
在参加爱德华生命科学年度分析师会议后，显然该公司的未来出现了积极的叙事。爱德华目前的市场估值似乎合理，待医师见解进一步支持。
爱德华生命科学在其年度投资者日上提供了具有前景的多年度展望，重申了其2024年指引并公布了与当前市场估计一致的2025年指引。
以下为今日8位分析师对$爱德华生命科学 (EW.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
